Amylase Release from Rat Parotid Gland Slices C.L

Total Page:16

File Type:pdf, Size:1020Kb

Amylase Release from Rat Parotid Gland Slices C.L Br. J. P!harmnic. (1981) 73, 517-523 THE EFFECTS OF SUBSTANCE P AND RELATED PEPTIDES ON a- AMYLASE RELEASE FROM RAT PAROTID GLAND SLICES C.L. BROWN & M.R. HANLEY MRC Neurochemical Pharmacology Unit, Medical Research Council Centre, Medical School, Hills Road, Cambridge CB2 2QH 1 The effects of substance P and related peptides on amylase release from rat parotid gland slices have been investigated. 2 Supramaximal concentrations (1 F.M) of substance P caused enhancement of amylase release over the basal level within 1 min; this lasted for at least 40 min at 30°C. 3 Substance P-stimulated amylase release was partially dependent on extracellular calcium and could be inhibited by 50% upon removal of extracellular calcium. 4 Substance P stimulated amylase release in a dose-dependent manner with an ED50 of 18 nm. 5 All C-terminal fragments of substance P were less potent than substance P in stimulating amylase release. The C-terminal hexapeptide of substance P was the minimum structure for potent activity in this system, having 1/3 to 1/8 the potency of substance P. There was a dramatic drop in potency for the C-terminal pentapeptide of substance P or substance P free acid. Physalaemin was more potent than substance P (ED50 = 7 nM), eledoisin was about equipotent with substance P (ED5o = 17 nM), and kassinin less potent than substance P (ED50 = 150 nM). 6 The structure-activity profile observed is very similar to that for stimulation of salivation in vivo, indicating that the same receptors are involved in mediating these responses. 7 All the fragments of substance P tested were capable of eliciting a full amylase release response. This indicates that the apparent partial agonist action of the C-terminal nonapeptide fragment on in vivo salivation is not explicable at the receptor level. Introduction The undecapeptide substance P was originally iden- channel mechanism (Putney, 1977; Gallacher & tified in extracts of horse intestine and was found to Petersen, 1980). cause hypotension and powerful contractions of in- In peripheral tissue bioassays, the potency rank testinal smooth muscle (Von Euler & Gaddum, order of synthetic C-terminal fragments of substance 1931). Substance P was subsequently isolated from P (Bury & Mashford, 1976; Blumberg & Teichberg, the hypothalamus, sequenced and synthesized 1979) or of tachykinins (naturally-occurring sub- (Chang & Leeman, 1970; Chang, Leeman & Niall, stance P-like peptides; Erspamer, Erspamer & Pic- 1971). cinelli, 1980), has been used as a tool to study the One of the most potent actions of substance P in substance P receptor. Experiments on in vivo saliva- peripheral tissues is the stimulation of salivation tion have shown that the minimum sequence for (Leeman & Hammerschlag, 1967). Upon systemic activity is the C-terminal pentapeptide, and all C- injection it can cause up to a 50 fold increase in terminal fragments of substance P have lower agonist salivary flow with a 4 fold increase in amylase release potency than substance P (Hanley, Lee, Jones & per unit volume of saliva (Liang & Cascieri, 1979). Michell, 1980). However, these data also showed an This appears to be a direct action of substance P on interesting anomaly; namely that the C-terminal sub- the glands themselves as it is not blocked in vivo by stance P nonapeptide behaved as a partial agonist atropine, propranolol or phenoxybenzamine and did not elicit a full response, unlike the other (Leeman & Hammerschlag, 1967). Moreover, in C-terminal fragments. vitro studies show several substance P effects on The investigation described here was undertaken salivary gland preparations (Rudich & Butcher, to determine the structural requirements of the sub- 1976; Friedman & Selinger, 1978; Jones & Michell, stance P receptor of rat salivary glands in vitro, using 1978; Gallacher & Petersen, 1980), and point to the the release of a-amylase from parotid slices. In so existence of separate a-adrenoceptor, substance P doing, we found that the apparent partial agonist and muscarinic receptors acting via a common ion activity of the C-terminal nonapeptide is not a true 0007-1188/81/060517-007 $01.00 ) Macmillan Publishers Ltd 1981 518 C.L. BROWN & M.R. HANLEY receptor phenomenon but is rather a complication of internal standards for each batch of tissue. The vials in vivo sialogogue experiments. We also describe the were gassed with 95% 02:5% C02, sealed and incu- characteristics of a-amylase release from parotid bated at 30°C with shaking for 30 min. Preliminary slices to support the use of this preparation as a model studies showed that stimulation of release was grea- of substance P receptor function. ter at 30°C than at 20°C. At the end of the 30 min incubation period, the contents of the vials were Methods transferred into 'Microfuge' tubes which were spun for 1 min at 10,000 gin a Beckman 'Microfuge'. The Preparation of the parotid slices supernatant was taken for a-amylase assay. A gassed (95% 02: 5% C02) Krebs-Ringer bicarbo- Amylase assay nate buffer containing 10mM inosine, 0.4mM adenine and 5 mm 3-hydroxybutyrate was used The supematant was diluted x 4 and 10 ,ul was incu- throughout (Batzri & Selinger, 1973). bated with 0.99 ml of starch solution (0.5 ml of starch For a typical experiment involving 36 incubations, solution in 0.1 M phosphate buffer (pH 7) diluted the parotid salivary glands were removed from three with 0.49 ml distilled water) at room temperature for male Sprague-Dawley rats, which had been anaes- 5 min. The reaction was stopped by addition of 1 ml thetized with chloroform and killed by exsanguina- of an alkaline solution of 3,5-dinitrosalicylic acid. tion. After removal, the glands were kept in the The mixture was heated in a boiling water bath for medium at room temperature. 10 min. After cooling, the contents were diluted with The glands were dissected free of lymph nodes, 10 ml of water and the absorbance (1 cm light path) at adipose and connective tissues and cut into small wavelength 546 nm was measured against a blank to pieces about 3 mm2 which were then cross chopped at which 10 ,ul of incubation medium had been added in 600 with a spacing of 0.15 mm on a Mcllwain tissue place of diluted supernatant. For each experiment, chopper. The resulting slices were placed in medium the amylase activity was expressed as maltose equi- (5 ml per pair of parotid glands) containing 0.5 mg/ml valents by comparison with a maltose standard curve. of collagenase, which was gently gassed with One unit of amylase is defined as the amount of 95% 02:5% C02, sealed, and incubated at 30°C for enzyme that causes the formation of 1 mg of maltose 30 min with shaking. The purpose of this treatment in 5 min at 25°C. Owing to between-experiment vari- was to remove the collagen fibres which tend to ation in the magnitude of the response, data were in clump the tissue slices. At the end of this incubation, some instances expressed as a percentage of the the collagenase solution was poured off and the stimulation by a supramaximal concentration of sub- treated slices rinsed three times with medium at stance P (1 I1.M) over the basal a-amylase release. 300C. In vivo salivation Preparation oftissueforcalcium-free incubation The increase in salivary flow provoked by substance A calcium-free medium was prepared by omitting P and other peptides was determined in rats as de- CaCI2 from the normal medium and replacing it on a scribed previously (Hanley et al., 1980). molar basis with MgCl2 and adding EGTA to a final concentration of 1 mm. The slices were prepared as Drugs described above and were then dispersed with a 50 times larger volume of calcium-free medium. The Synthetic substance P, C-terminal fragments of sub- slices were pipetted from the large volume of medium stance P, substance P free acid, eledoisin, when they had settled, rinsed again in calcium-free physalaemin and kassinin were obtained from Penin- medium and pipetted into incubation vials in sula Laboratories. Collagenase was obtained from calcium-free medium containing the various drug Worthington Biochemicals. additions. Incubation oftissue slices Results Volumes of 20 9LI of the suspension of parotid slices Characteristics of response (0.2 mg wet weight) were pipetted into flat-bottomed polypropylene vials containing 470 L1 of the medium Substance P stimulation of amylase release was ap- and 10 I of drug solution. Triplicate experiments parent within 1 min and lasted for at least 40 min were performed for each drug concentration. Tubes (Figure 1). There was an initial steep rise in basal containing no drugs (basal) and tubes containing amylase release and of amylase release stimulated by 1 ,LM substance P (supramaximal) were included as a supramaximal concentration of substance P (1 FM) SUBSTANCE P-STIMULATED PAROTID AMYLASE RELEASE 519 125 which slowed after about 2 min. From 10 to 40 min there was a constant rate of amylase release which was greater in the presence of 1 ,JM substance P than in the absence of drug. These time courses indicate that 30 min is a suitable incubation time to choose for 100 the study of stimulation of amylase release by sub- stance P and related peptides. When carbachol, noradrenaline and substance P were used in supramaximal concentrations, no com- c0 bination of agonists produced a summated amylase of 75 release response (Table 1). The stimulation amyl- 'aC ase release by a supramaximal concentration of car- bachol (500 F±M) was not significantly different from that elicited by 1 ,uM substance P. However, sup- In ramaximal noradrenaline (500 ,uM) produced a sig- nificantly greater stimulation of amylase release than 0Cu 50 a) did either carbachol or substance P.
Recommended publications
  • V·M·I University Microfilms International a Bell & Howell Information Company 300 North Zeeb Road, Ann Arbor
    Characterization of the cloned neurokinin A receptor transfected in murine fibroblasts Item Type text; Dissertation-Reproduction (electronic) Authors Henderson, Alden Keith. Publisher The University of Arizona. Rights Copyright © is held by the author. Digital access to this material is made possible by the University Libraries, University of Arizona. Further transmission, reproduction or presentation (such as public display or performance) of protected items is prohibited except with permission of the author. Download date 27/09/2021 18:29:56 Link to Item http://hdl.handle.net/10150/185828 1/. INFORMATION TO USERS This manuscript has been reproduced from the microfilm master. UMI films the text directly from the original or copy submitted. Thus, some thesis and dissertation copies are in typewriter face, while others may be from any type of computer printer. The quality of this reproduction is dependent upon the quality of the copy submitted. Broken or indistinct print, colored or poor quality illustrations and photographs, print bleed through, substandard margins, and improper alignment can adversely affect reproduction. In the unlikely event that the author did not send UMI a complete manuscript and there are missing pages, these will be noted. Also, if unauthorized copyright material had to be removed, a note. will indicate the deletion. Oversize materials (e.g., maps, drawings, charts) are reproduced by sectioning the original, beginning at the upper left-hand corner and continuing from left to right in equal sections with small overlaps. Each original is also photographed in one exposure and is included in reduced form at the back of the book. Photographs included in the original manuscript have been reproduced xerographically in this copy.
    [Show full text]
  • Identification of a Novel Vasodilatory Octapeptide from the Skin Secretion
    molecules Article Identification of a Novel Vasodilatory Octapeptide from the Skin Secretion of the African Hyperoliid Frog, Kassina senegalensis Qiang Du 1,†, Hui Wang 1,*,†, Chengbang Ma 2, Yue Wu 2, Xinping Xi 2,*, Mei Zhou 2 ID , Tianbao Chen 2 ID , Chris Shaw 2 and Lei Wang 2 1 School of Pharmacy, China Medical University, Shenyang 110001, Liaoning, China; [email protected] 2 Natural Drug Discovery Group, School of Pharmacy, Queen’s University, Belfast BT9 7BL, Northern Ireland, UK; [email protected] (C.M.); [email protected] (Y.W.); [email protected] (M.Z.); [email protected] (T.C.); [email protected] (C.S.); [email protected] (L.W.) * Correspondence: [email protected] (H.W.); [email protected] (X.X.); Tel.: +86-24-2325-6666 (H.W.); +44-28-9097-2200 (X.X.); Fax: +86-2325-5471 (H.W.); +44-28-9094-7794 (X.X.) † These authors contributed equally to this work. Received: 5 July 2017; Accepted: 19 July 2017; Published: 19 July 2017 Abstract: The defensive skin secretions of amphibians continue to be an excellent source of novel biologically-active peptides. Here we report the identification and pharmacological activity of a novel C-terminally amided myotropic octapeptide from the skin secretion of the African hyperoliid frog, Kassina senegalensis. The 8-amino acid peptide has the following primary structure: WMSLGWSL-amide and has a molecular mass of 978 Da. The primary structure and organisation of the biosynthetic precursor of WL-8 amide was successfully deduced from cloned skin secretion-derived cDNA.
    [Show full text]
  • Peptide Chemistry up to Its Present State
    Appendix In this Appendix biographical sketches are compiled of many scientists who have made notable contributions to the development of peptide chemistry up to its present state. We have tried to consider names mainly connected with important events during the earlier periods of peptide history, but could not include all authors mentioned in the text of this book. This is particularly true for the more recent decades when the number of peptide chemists and biologists increased to such an extent that their enumeration would have gone beyond the scope of this Appendix. 250 Appendix Plate 8. Emil Abderhalden (1877-1950), Photo Plate 9. S. Akabori Leopoldina, Halle J Plate 10. Ernst Bayer Plate 11. Karel Blaha (1926-1988) Appendix 251 Plate 12. Max Brenner Plate 13. Hans Brockmann (1903-1988) Plate 14. Victor Bruckner (1900- 1980) Plate 15. Pehr V. Edman (1916- 1977) 252 Appendix Plate 16. Lyman C. Craig (1906-1974) Plate 17. Vittorio Erspamer Plate 18. Joseph S. Fruton, Biochemist and Historian Appendix 253 Plate 19. Rolf Geiger (1923-1988) Plate 20. Wolfgang Konig Plate 21. Dorothy Hodgkins Plate. 22. Franz Hofmeister (1850-1922), (Fischer, biograph. Lexikon) 254 Appendix Plate 23. The picture shows the late Professor 1.E. Jorpes (r.j and Professor V. Mutt during their favorite pastime in the archipelago on the Baltic near Stockholm Plate 24. Ephraim Katchalski (Katzir) Plate 25. Abraham Patchornik Appendix 255 Plate 26. P.G. Katsoyannis Plate 27. George W. Kenner (1922-1978) Plate 28. Edger Lederer (1908- 1988) Plate 29. Hennann Leuchs (1879-1945) 256 Appendix Plate 30. Choh Hao Li (1913-1987) Plate 31.
    [Show full text]
  • Neuropeptide Proctolin (H-Arg-Tyr-Leu-Pro-Thr-OH)
    Proc. NatL Acad. Sci. USA Vol. 78, No. 9, pp. 5899-5902, September 1981 Neurobiology Neuropeptide proctolin (H-Arg-Tyr-Leu-Pro-Thr-OH): Immunological detection and neuronal localization in insect central nervous system (peptide neurotransmitter/identified neurons) CYNTHIA A. BISHOP, MICHAEL O'SHEA*, AND RICHARD J. MILLER The Department of Pharmacological and Physiological Sciences, The University of Chicago, 947 E. 58th Street, Chicago, Illinois 60637 Communicated by Solomon H. Snyder, June 19, 1981 ABSTRACT Proctolin (H-Arg-Tyr-Leu-Pro-Thr-OH) is a pen- vestigation ofneuropeptide action in a relatively simple nervous tapeptide first extracted from cockroaches. It is known to have system. many neurohormonal effects and has been associated with spe- cific, identified cockroach neurons. We have produced proctolin MATERIALS AND METHODS antisera and report here on their application in detecting proc- tolin-like immunoreactivity (PLI) in the cockroach central nervous Adult specimens, both male and female, of the large American system. Radioimmunoassay, capable ofdetecting 50 fmol ofproc- cockroach (Periplaneta americana; Carolina Biological Supply, tolin, was used to quantify the distribution of PLI. Highest con- Burlington, NC) were used. Authentic proctolin for immuni- centrations were detected in the genital ganglia and lowest in the zation was obtained from Sigma. Enkephalins were.a gift of S. cerebral ganglia. Immunohistochemistry on the cockroach central Wilkinson, Wellcome Research Laboratories (Beckenham, nervous system demonstrated that PLI is localized to neurons. Kent, England). Gut bombesin was a gift of J. Rivier, Salk In- Neurons stained by using immunohistochemistry were widespread stitute (La Jolla, CA). Other peptides were obtained from in the ganglia.
    [Show full text]
  • A 0.70% E 0.80% Is 0.90%
    US 20080317666A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317666 A1 Fattal et al. (43) Pub. Date: Dec. 25, 2008 (54) COLONIC DELIVERY OF ACTIVE AGENTS Publication Classification (51) Int. Cl. (76) Inventors: Elias Fattal, Paris (FR); Antoine A6IR 9/00 (2006.01) Andremont, Malakoff (FR); A61R 49/00 (2006.01) Patrick Couvreur, A6II 5L/12 (2006.01) Villebon-sur-Yvette (FR); Sandrine A6IPI/00 (2006.01) Bourgeois, Lyon (FR) (52) U.S. Cl. .......................... 424/1.11; 424/423; 424/9.1 (57) ABSTRACT Correspondence Address: Drug delivery devices that are orally administered, and that David S. Bradlin release active ingredients in the colon, are disclosed. In one Womble Carlyle Sandridge & Rice embodiment, the active ingredients are those that inactivate P.O.BOX 7037 antibiotics, such as macrollides, quinolones and beta-lactam Atlanta, GA 30359-0037 (US) containing antibiotics. One example of a Suitable active agent is an enzyme Such as beta-lactamases. In another embodi ment, the active agents are those that specifically treat colonic (21) Appl. No.: 11/628,832 disorders, such as Chrohn's Disease, irritable bowel syn drome, ulcerative colitis, colorectal cancer or constipation. (22) PCT Filed: Feb. 9, 2006 The drug delivery devices are in the form of beads of pectin, crosslinked with calcium and reticulated with polyethylene imine. The high crosslink density of the polyethyleneimine is (86). PCT No.: PCT/GBO6/OO448 believed to stabilize the pectin beads for a sufficient amount of time such that a Substantial amount of the active ingredi S371 (c)(1), ents can be administered directly to the colon.
    [Show full text]
  • 251-Bolton-Hunter- Labeled Substance P Binding Sites in Rat Spinal Cord’
    0270.6474/65/0505-1293$02.00/O The Journal of Neuroscience Copyright 0 Society for Neuroscience Vol. 5, No. 5, pp. 1293-1299 Printed in U.S.A. May 1985 Characterization and Segmental Distribution of ‘251-Bolton-Hunter- labeled Substance P Binding Sites in Rat Spinal Cord’ CLIVEL G. CHARLTON’ AND CINDA J. HELKE Department of Pharmacology, Uniformed Services University of the Health Sciences, Bethesda, Maryland 20814 Abstract al., 1982) are two sources for SP in the ventral horn. The nucleus interfascicularis hypoglossi also supplies SP-containing nerve termi- Substance P (SP) is widely distributed in the spinal cord nals to the IML cells of origin for autonomic preganglion fibers (Helke and has been implicated as a neurotransmitter in several et al., 1982). spinal cord neuronal systems. To investigate SP receptors in Functional studies support the concept of a neurotransmOitter role the spinal cord, 1251-Bolton-Hunter-SP (‘*‘I-BH-SP) was used for SP in the spinal cord. Nociception (Piercey et al., 1981; Akerman to identify and characterize spinal cord binding sites for the et al., 1982; Fasmer and Post, 1983) motor control (Otsuka and peptide. The binding of ‘*%BH-SP had the following charac- Konishi, 1977; Yanagisawa et al., 1982) and certain autonomic teristics: high affinity; time, temperature, and membrane con- functions (Loewy and Sawyer, 1982; Keeler and Helke, 1984) are centration dependent; reversible; and saturable. The KS0 of modulated by spinal cord SP. In addition, SP receptors in the spinal SP in whole spinal cord was 0.46 nM as compared with 0.95, cord have been demonstrated by iontophoretic studies in which SP 60, and 150 nM for physalaemin, eledoisin, and kassinin.
    [Show full text]
  • Intracerebroventricular Responses to Neuropeptide Y in the Antagonists
    British Journal of Pharmacology (1996) 117, 241-249 B 1996 Stockton Press All rights reserved 0007-1188/96 $12.00 9 Intracerebroventricular responses to neuropeptide y in the conscious rat: characterization of its receptor with selective antagonists Pierre Picard & 'Rejean Couture Department of Physiology, Faculty of Medicine, Universite de Montreal, C.P. 6128, Succursale Centre-Ville, Montreal, Quebec, Canada H3C 3J7 1 The cardiovascular and behavioural effects elicited by the intracerebroventricular (i.c.v.) administration of neuropeptide y (NPy) in the conscious rat were assessed before and 5 min after i.c.v. pretreatment with antagonists selective for NKI (RP 67,580), NK2 (SR 48,968) and NK3 (R 820) receptors. In addition, the central effects of NPy before and after desensitization of the NK, and NK2 receptors with high doses of substance P (SP) and neurokinin A (NKA) were compared. 2 Intracerebroventricular injection of NPy (10-780 pmol) evoked dose- and time-dependent increases in mean arterial blood pressure (MAP), heart rate (HR), face washing, head scratching, grooming and wet-dog shake behaviours. Similar injection of vehicle or 1 pmol NPy had no significant effect on those parameters. 3 The cardiovascular and behavioural responses elicited by NPy (25 pmol) were significantly and dose- dependently reduced by pretreatment with 650 pmol and 6.5 nmol of SR 48,968. No inhibition of NPy responses was observed when 6.5 nmol of RP 67,580 was used in a similar study. Moreover, the prior co-administration of SR 48,968 (6.5 nmol) and RP 67,580 (6.5 nmol) with or without R 820 (6.5 nmol) did not reduce further the central effects of NPy and significant residual responses (30-50%) remained.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Targeting the Vasopressin Type 2 Receptor for Renal Cell Carcinoma Therapy
    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Oncogene Manuscript Author . Author manuscript; Manuscript Author available in PMC 2020 April 15. Published in final edited form as: Oncogene. 2020 February ; 39(6): 1231–1245. doi:10.1038/s41388-019-1059-0. Targeting the Vasopressin Type 2 Receptor for Renal Cell Carcinoma Therapy Sonali Sinhaa,b, Nidhi Dwivedia,b, Shixin Taoa,b, Abeda Jamadara,b, Vijayakumar R Kakadea,b, Maura O’Neilc, Robert H Weissd,e, Jonathan Endersf, James P Calveta,h,i, Sufi M Thomasg,i, Reena Raoa,b,i aThe Jared Grantham Kidney Institute, University of Kansas Medical Center, Kansas City,KS. bDepartment of Internal Medicine, University of Kansas Medical Center, Kansas City, KS. cDepartment of Pathology and Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS. dDivision of Nephrology and Comprehensive Cancer Center, University of California, Davis, CA. eMedical Service, VA Northern California Health Care System, Sacramento, CA. fDepartment of Anatomy and Cell Biology, University of Kansas Medical Center, Kansas City, KS. gDepartment of Otolaryngology, University of Kansas Medical Center, Kansas City, KS. hDepartment of Biochemistry and Molecular Biology, University of Kansas Medical Center, Kansas City, KS. iDepartment of Cancer Biology, University of Kansas Medical Center, Kansas City, KS. Abstract Arginine vasopressin (AVP) and its type-2 receptor (V2R) play an essential role in the regulation of salt and water homeostasis by the kidneys. V2R activation also stimulates proliferation of renal cell carcinoma (RCC) cell lines in vitro. The current studies investigated V2R expression and activity in human RCC tumors, and its role in RCC tumor growth.
    [Show full text]
  • Topography of a Binding Site for Small Amnestic Peptides Deduced from Structure-Activity Studies: Relation to Amnestic Effect of Amyloid F8 Protein JAMES F
    Proc. Natl. Acad. Sci. USA Vol. 91, pp. 380-384, January 1994 Neurobiology Topography of a binding site for small amnestic peptides deduced from structure-activity studies: Relation to amnestic effect of amyloid f8 protein JAMES F. FLOOD*, EUGENE ROBERTStt, MARK A. SHERMAN§, BRUCE E. KAPLAN§, AND JOHN E. MORLEY* Geriatric Research Education and Clinical Center (GRECC), Veterans Administration Medical Center, St. Louis, MO 63106, and St. Louis University School of Medicine, Division of Geriatric Medicine, St. Louis, MO 63104; and tDepartment of Neurobiochemistry and §Biology Division, Beckman Research Institute of the City of Hope, Duarte, CA 91010 Contributed by Eugene Roberts, September 7, 1993 ABSTRACT Four peptides homologous to amyloid (B pro- With the exception of commercially purchased peptides tein containng the Val-Phe-Phe (VFF) sequence administered VF and FV, all peptides used in these studies were synthe- intracerebroventricularly after training caused amnesia for sized and analyzed to establish purity by standard methods. footshock active avoidance training in mice. Results with VFF Prior to neutralization and appropriate dilution with saline, and other peptides containing VFF or portions thereof were peptides were dissolved in (i) saline, (ii) dimethyl sulfoxide, used to generate a topographic map for a hypothetical binding (iii) glacial acetic acid, or (iv) NaOH. Upon testing for surface for amnestic peptides, termed Z. Effects on retention of retention of FAAT, groups receiving posttraining icv admin- footshock active avoidance training were rationalized in terms istration of2 1d ofappropriate dilutions ofthe above vehicles of flt to Z, making possible design of potential memory- showed no significant differences among them (ANOVA, F modulating peptidic and nonpeptidic substances.
    [Show full text]
  • Back Matter (PDF)
    MOLECULAR PHARMACOLOGY 26:605-609 AUTHOR INDEX FOR VOLUME 26 A berg, Aaron, Watanabe, Kyoichi A., Fox, Jack J., and Philips, Frederick S. Metabolic Competition Studies of 2’-Fluoro-S-iodo-l- Albengres, Edith. See Urien, Riant, Brioude, and Tillement, 322 f3-D-arabinofuranosylcytosine in Vero Cells and Herpes Simplex Albuquerque, E. X. See Aracava, Ikeda, Daly, and Brooks, 304 Type 1-Infected Vero Cells, 587 See Ikeda, Aronstam, Daly, and Aracava, 293 Christie, Nelwyn T. See Cantoni, Swann, Drath, and Costa, 360 Ambler, S. Kelly, Brown, R. Dale, and Taylor, Palmer. The Chrivia, John. See Bolger, Dionne, Johnson, and Taylor, 57 Relationship between Phosphatidylinositol Metabolism and Mobili- Colacino, Joseph M. See Chou, Lopez, Feinberg, Watanabe, Fox, and zation of Intracellular Calcium Elicited by Alpha,-Adrenergic Recep- Philips, 587 tar Stimulation in BC3H-1 Muscle Cells, 405 Collins, Sheila, and Marletta, Michael A. Carcinogen-Binding Aracava, Y. Ikeda, S. R., Daly, J. W., Brookes, N., and Albu- Proteins: High-Affinity Binding Sites for Benzo[ajpyrene in Mouse querque, E. X. Interactions of Bupivacaine with Ionic Channels of Liver Distinct from the Ah Receptor, 353 the Nicotonic Receptor: Analysis of Single-Channel Currents, 304 Cooper, Dermot M. F. See Sadler and Mailer, 526 See Ikeda, Aronstam, Daly, and Albuquerque, 293 Corbett, Michael D. See Doerge, 348 Aronstam, R. S. See Ikeda, S. R. , Daly, J. W., Aracava, Y. , and Cormier, Ethel. See Jordan, Lieberman, Koch, Bagley, and Ruenitz, Albuquerque, E. X. , 293 272 Aub, Debra L. See Putney, McKinney, and Leslie, 261 Costa, Erminio. See Quach, Tang, Kageyama, Mocchetti, Guidotti, Meek, and Schwartz, 255 B Costa, Max.
    [Show full text]
  • Occurrence of Bombesin and Alytesin in Extracts of the Skin of Three
    Br. J. Pharmac. (1972), 45, 333-348. Occurrence of bombesin and alytesin in extracts of the skin of three European discoglossid frogs and pharmacological actions of bombesin on extravascular smooth muscle V. ERSPAMER, G. FALCONIERI ERSPAMER, M. INSELVINI AND L. NEGRI Institute of Medical Pharmacology I, University of Rome, Rome, Italy Summary 1. Methanol extracts of the skin of Bombina bombina and Bombina variegata variegata, two European discoglossid frogs, contain an active tetradecapeptide, bombesin. Alytesin, a tetradecapeptide strictly related to bombesin is present in extracts of the skin of Alytes obstetricans, another European discoglossid frog. The American frog Rana pipiens, contains in its skin ranatensin, an endecapeptide related to bombesin and alytesin. 2. Passage of crude skin extracts of Bombina through a column of alumina yields eluates which may be considered free of other peptide contaminants and are suitable for the isolation of bombesin in a pure form. 3. Bombesin has a stimulant action on several preparations of intestinal, uterine and urinary tract smooth muscle. Sometimes the effect is easily repeatable and shows a fair proportionality to the dose, but at other times a prompt and intense tachyphylaxis is observed. Other smooth muscle prepara- tions are poorly sensitive or insensitive to bombesin. The rat uterus, the kitten small intestine, the guinea-pig colon and the rat urinary bladder may be used for the quantitative bioassay of bombesin. 4. Bombesin-like peptides may easily be distinguished from all other naturally occurring peptides by parallel assay. They constitute a new group of active peptides possessing a peculiar spectrum of activity. Introduction Methanol extracts of the skin of the two European discoglossid frogs Bombina bombina and Bombina variegata variegata contain a principle which displays a number of pharmacological actions on vascular and extravascular smooth muscle and on gastric secretion (Erspamer, Falconieri Erspamer & Inselvini, 1970; Melchiorri, Sopranzi & Erspamer, 1971).
    [Show full text]